# Clinical Trial to Assess Safety and Efficacy of Combination Therapy: Hydroxychloroquine, Pegylated Interferon Alpha-2a and Ribavirin in Chronic Hepatitis C Subjects Non-responders to the Standard of Care Therapy.

> **NCT01272310** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Sheba Medical Center** · enrollment: 36 (estimated)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **BIOLOGICAL:** Hydroxychloroquine (HCQ), Pegylated Interferon Alpha-2a (Peg-IFN alpha-2a) and Ribavirin

## Key facts

- **NCT ID:** NCT01272310
- **Lead sponsor:** Sheba Medical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-01
- **Primary completion:** 2012-01
- **Final completion:** 2013-07
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2011-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01272310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01272310, "Clinical Trial to Assess Safety and Efficacy of Combination Therapy: Hydroxychloroquine, Pegylated Interferon Alpha-2a and Ribavirin in Chronic Hepatitis C Subjects Non-responders to the Standard of Care Therapy.". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01272310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*